Galera Therapeutics, Inc. GRTX
We take great care to ensure that the data presented and summarized in this overview for Galera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GRTX
View all-
Gsa Capital Partners LLP London, X03.63MShares$508,5670.04% of portfolio
-
Blackstone Inc New York, NY1.68MShares$235,0570.0% of portfolio
-
Abrdn PLC898KShares$125,7720.0% of portfolio
-
Tekla Capital Management LLC898KShares$125,7720.11% of portfolio
-
Nan Fung Group Holdings LTD Central, K3613KShares$85,8510.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA448KShares$62,7660.0% of portfolio
-
Geode Capital Management, LLC Boston, MA440KShares$61,6480.0% of portfolio
-
Black Rock Inc. New York, NY357KShares$50,0060.0% of portfolio
-
Atom Investors LP Austin, TX356KShares$49,8680.01% of portfolio
-
Ubs Group Ag294KShares$41,0900.0% of portfolio
Latest Institutional Activity in GRTX
Top Purchases
Top Sells
About GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Insider Transactions at GRTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.83%
|
$0
$0.17 P/Share
|
|
Feb 07
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
175,000
+1.09%
|
$0
$0.17 P/Share
|
|
Feb 06
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
25,000
+0.32%
|
$0
$0.2 P/Share
|
|
Feb 05
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
97,402
+1.25%
|
$0
$0.18 P/Share
|
|
Jan 30
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
335,000
+4.22%
|
$0
$0.18 P/Share
|
|
Jan 29
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+2.02%
|
$0
$0.18 P/Share
|
|
Mar 16
2023
|
Mark Bachleda Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
11,000
+50.0%
|
$22,000
$2.25 P/Share
|
|
Mar 13
2023
|
Chris Degnan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.96 P/Share
|
|
Mar 10
2023
|
Mel Sorensen President and CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+23.15%
|
$100,000
$1.68 P/Share
|
|
Nov 21
2022
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.46%
|
$10,000
$1.07 P/Share
|
|
Sep 12
2022
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+9.24%
|
$10,000
$1.07 P/Share
|
|
Jul 18
2022
|
Lawrence M Alleva |
SELL
Bona fide gift
|
Direct |
4,000
-63.24%
|
-
|
|
Dec 17
2021
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+18.49%
|
$20,000
$1.07 P/Share
|
|
Dec 17
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
20,000
+25.0%
|
$40,000
$2.74 P/Share
|
|
Sep 01
2021
|
Jon T Holmlund Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
47,756
-100.0%
|
$382,048
$8.47 P/Share
|
|
Sep 01
2021
|
Jon T Holmlund Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,756
+50.0%
|
$95,512
$2.43 P/Share
|
|
Jun 15
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+20.0%
|
$90,000
$9.13 P/Share
|
|
Jun 02
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$80,000
$8.65 P/Share
|
|
Jun 01
2021
|
Lawrence M Alleva |
BUY
Open market or private purchase
|
Indirect |
4,045
+50.0%
|
$32,360
$8.59 P/Share
|
|
Jun 01
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$80,000
$8.64 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 932K shares |
|---|